Because peripheral blood is easily accessible and provides an important biological resource for diagnosis and monitoring disease progression of cancer patients, combined analyses of CTCs and serum AFP levels with one blood draw can be performed more frequently than imaging and could pave the way for monitoring the disease status and treatment response of HCC patients. Here, AFP is linked to hepatocellular carcinoma.